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Abstract The helix^loop^helix transcription factor NeuroD1
(also known as Beta2) is involved in L-cell survival during devel-
opment and insulin gene transcription in adults. Here we show
NeuroD1 is primarily cytoplasmic at non-stimulating glucose
concentrations (i.e. 3 mM) in MIN6 L-cells and nuclear under
stimulating conditions (i.e. 20 mM). Quanti¢cation revealed
that NeuroD1 was in 40^45% of the nuclei at 3 mM and 80^
90% at 20 mM. Treatment with the MEK inhibitor PD98059 or
substitution of a serine for an alanine at a potential mitogen-
activated protein kinase phosphorylation site (S274) in NeuroD1
signi¢cantly increased the cytoplasmic level at 20 mM glucose.
The rise in NeuroD1-mediated transcription in response to glu-
cose also correlated with the change in sub-cellular localization,
a response attenuated by PD98059. The data strongly suggest
that glucose-stimulation of the MEK^ERK signalling pathway
in£uences NeuroD1 activity at least partially through e¡ects on
sub-cellular localization. ; 2002 Federation of European Bio-
chemical Societies. Published by Elsevier Science B.V. All
rights reserved.
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1. Introduction
Insulin produced from pancreatic islet L-cells plays a vital
role in the maintenance of glucose homeostasis. Insulin is
uniquely expressed in L-cells where elevated glucose levels
lead to increased insulin transcription, biosynthesis, and secre-
tion. The cis-acting elements controlling insulin gene expres-
sion are located within the mammalian insulin enhancer re-
gion, which is found between nucleotides 3340 and 391
relative to the transcription start site [1,2]. Several key control
elements within this region have been identi¢ed, including the
conserved C2 (3317 to 3311 base pairs (bp) [3], A3 (3201 to
3196 bp) [4,5], C1/RIPE3b (3118 to 3107 bp) [6,7] and E1
(3100 to 391 bp) [8^11] elements. Mutations that decrease
the binding a⁄nity of the A3, C1/RIPE3b, and E1 activators
reduce both glucose-regulated and L-cell-type-speci¢c tran-
scription from insulin gene reporter constructs [12^16].
The activator of insulin A3 element stimulated transcription
is the PDX-1 homeodomain protein (also known as IPF-1,
STF-1, and IDX-1 [17^19]). Endogenous insulin gene expres-
sion is activated upon ectopic expression of PDX-1 in K-cell
lines [20,21], while profoundly reduced upon ablating pdx1
expression selectively in L-cells of mice in vivo [22]. Elevated
glucose levels induce the PDX-1 binding and trans-activation
domain (AD) activity [23^25]. PDX-1 is phosphorylated in
response to glucose, although it is unclear if PI3 kinase
[26,27] or p38 SAPK [28] is directly involved in these signal-
ling events. Although the insulin C1 element activator, RI-
PE3b1, has not been isolated, the DNA-binding potential of
this factor also appears to be regulated by phosphorylation
[29]. The activator of the insulin E1 element is a heterodimer,
composed of proteins in the basic helix^loop^helix family that
are enriched in islets (NeuroD1 [30]/BETA2 [31]) and gener-
ally distributed (HEB [32] and E2A [33^35]).
Gene ablation experiments performed in mice on PDX-1
and NeuroD1 has clearly established a key role for each in
pancreatic development. Thus, the expression of PDX-1 in
precursor cells appears to be essential for the development
of both the endocrine and exocrine compartments of the pan-
creas [36,37], whereas NeuroD1 [38] acts at a later stage of
pancreatic development, involving islet cell formation and
maintenance. Mutations in NeuroD1 [38,39] and PDX-1
[22,40,41] cause diabetes in both humans and mice, providing
further support for each as a central regulator of L-cell phys-
iological function.
In contrast to PDX-1, little is known about how glucose
stimulates NeuroD1 activity. Here we show that NeuroD1 is
in the nucleus under stimulating glucose conditions, and pre-
dominantly cytoplasmic under non-stimulating. Our results
also suggest that the MEK^ERK signalling pathway mediates
the increased transcriptional and nuclear localization activity
of NeuroD1 in response to glucose. We propose phosphory-
lation in£uences NeuroD1 activation by a¡ecting partitioning
into the nucleus, and possibly through interactions with other
transcriptional regulatory factors.
2. Materials and methods
2.1. MIN6 cell transfections
MIN6 cells [42] were grown in Dulbecco’s modi¢ed Eagle’s medium
(DMEM) containing 4500 mg glucose/l (Gibco) with 15% fetal calf
serum (FCS; Gibco), penicillin (100 U/ml), streptomycin (100 mg/ml)
(Gibco) and 50 WM L-mercaptoethanol. Cells between passages 26 and
31 were transfected in 6-well dishes using Lipofectamine 2000 (Prom-
ega) in OPTIMEM (Gibco) as described by the manufacturer. Brie£y,
cell at 70^80% con£uency were transfected with 5.5 Wg of total DNA
(3 Wg of G5b-CAT (chloramphenicol acetyl transferase) reporter, 1.5
Wg Gal4-NeuroD156-355, 1 Wg pGL2RSV luciferase (as a control for
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the transfection e⁄ciency) together with 15 Wl of Lipofectamine 2000.
(The Gal4-NeuroD1 construct contains amino acids 156^356 of Neu-
roD1 fused in-frame to the to the DNA-binding domain of the Sac-
charomyces cerevisiae GAL4 transcription factor [43]. Four hours lat-
er the transfection mix was removed by addition of 2 ml of RPMI
1640 (Gibco; 0 mM glucose)+10% FCS. Glucose at either 3 or 20 mM
was then added. The cells were harvested after 16 h and luciferase
(Promega) and CAT assays performed [44]. The CAT activity of each
sample was normalized to the protein content (Bio-Rad) of the ex-
tract.
2.2. Sub-cellular localization of NeuroD
MIN6 cells (passage 26^31) at 70^80% con£uency were transfected
in 200 ml culture £asks using either 40 Wg hemagglutinin (HA)-Neu-
roD1 or green £uorescence protein (GFP)-NeuroD1 and 120 Wl Lipo-
fectamine 2000. The media was changed after 4 h to DMEM contain-
ing 15% FCS, 4500 mg/l glucose and 50 WM L-mercaptoethanol and
incubated for an additional 16^20 h. The cells were then trypsinized
and seeded on chamber slides. After an overnight incubation, the cells
were washed in RPMI 1640 (0 mM glucose)+10% FCS, and media
added containing either 3 or 20 mM glucose. The cells were ¢xed in
1% PFA after an overnight incubation. Immunocytochemistry was
performed as described [45] using a monoclonal antibody to HA
from Babco (0.5 Wg/ml) and a FITC-conjugated secondary antibody
1:100. A Hamamatsu C5810 cooled CCD camera on a BX51 Olym-
pus microscope was used to record images. Images were captured with
Image Pro software and processed in Adobe Photoshop 5.0.
2.3. DNA constructs
2.3.1. pBK-RSV-NeuroD1. The rat NeuroD1 cDNA was cloned
into pBK-RSV (Stratagene) using oligo-dT primed cDNA obtained
by RT-PCR from the MSL-G2-IN rat insulinoma [46] and speci¢c 5P
(5P-CCTGTTGGATCCAGGAAGTGGAAACATGA-3P) and 3P (5P-TG-
AAACTCGAGAGCCTCTAATCGTGAAAGAT-3P) primers. The
resulting PCR fragment was BamHI and XhoI digested and ligated
into the BamHI and XhoI site of pBK-RSV.
2.3.2. HA-NeuroD1. pBK-RSV-NeuroD1 was digested with XbaI
and KpnI and a 700 bp NeuroD fragment puri¢ed. A PCR fragment
containing the additional 380 bp of NeuroD and a new BamHI and
KpnI site was obtained using the 5P primer: 5P-ATGGGAGGATC-
CACCAAATCATAC3-P and the 3P primer: 5P-GAGTAGCAGGG-
TACCACCTTTCTC3-P. The PCR fragment was digested with Bam-
HI and KpnI and puri¢ed. The 700 bp DNA fragment and the PCR
fragment were ligated together into the BamHI and XbaI site of the
pcDNAI-Amp-HA vector (which was obtained by excising Ngn3 from
pcDNAI/Amp-HA-Ngn3 using BamHI and XbaI (a kind gift from
F. Guillemot)).
Point mutations within HA-NeuroD1 were introduced using the
QuickChange site-directed mutagenesis kit (Stratagene) with the fol-
lowing oligonucleotides (the mutated nucleotides are in bold and ital-
icized): HA-NeuroDS259A: F: 5P-CTTCTTTGAAGCCCCCCTAA-
CT-3P ; R: 5P-AGTTAGGGGGGCTTCAAAGAAG-3P, HA-Neuro-
DT262A: F: 5P-AAAGCCCCCTAGCTGATTGCACC-3P; R: 5P-GG-
TGCAATCAGCTAGGGGGCTTT-3P, HA-NeuroDS266A: F: 5P-TG-
ATTGCACCGCCCCTTCCTTT-3P ; R: 5P-AAAGGAAGGGGCGG-
TGCAATCA-3P, HA-NeuroDS274A: F: 5P-ACGGACCCCTCGCC-
CCGCCGCTCA-3P ; R: 5P-TGAGCGGCGGGGCGAGGGGTCC-
GT-3P, HA-NeuroDS274D: F: 5P-ACGGACCCCTGGATCCGCCG-
CTCA-3P ; R: 5P-TGAGCGGCGGATCCAGGGGTCCGT-3P.
2.3.3. GFP-NeuroD1. NeuroD1 sequences were cut out from HA-
NeuroD using XbaI and BamHI and cloned into the XbaI and BamHI
site in the pECFG-C1 vector (Clontech).
3. Results
3.1. Partitioning of NeuroD1 into the nucleus is in£uenced by
glucose
To investigate if glucose levels a¡ected the sub-cellular lo-
calization of NeuroD1, HA and GFP tagged versions of the
factor were constructed and transiently transfected into MIN6
cells. Both tagged constructs were principally located in the
cytoplasm at low, non-stimulating glucose concentrations (3
mM; Fig. 1A,B), and in the nucleus under stimulating con-
ditions (20 mM; Fig. 1C,D). Quanti¢cation revealed that 40^
45% of tagged NeuroD1 was in the nucleus of 3 mM glucose-
treated cells, as compared to 80^90% in 20 mM (Fig. 2).
Furthermore, transfection of primary isolated islet cells with
HA-NeuroD1 showed only expression of the HA-NeuroD in
the nucleus of islet cells grown in 20 mM glucose (data not
shown).
To examine whether the sub-cellular redistribution of Neu-
roD1 was also dependent on the MEK^ERK, PI3K, or
p38SAPK signalling, HA-NeuroD1-transfected MIN6 cells
Fig. 1. Glucose induces the translocation of NeuroD1 into the nucleus. MIN6 cells were transiently transfected with (A,C) HA-NeuroD1 or
(B,D) GFP-NeuroD1. The transfection cells were preincubated for 1 h in 0 mM glucose followed by 16 h in 3 or 20 mM glucose. The ¢xed
HA-NeuroD1-transfected cells were stained for NeuroD1 expression using an antibody against HA (Babco) followed by a FITC-conjugated sec-
ondary antibody, whereas the GFP-Neuro1-transfected cells were examined directly by £uorescence microscopy using a FITC ¢lter.
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were treated with pathway-speci¢c inhibitors (MEK, 50 WM
PD98059; PI3K, 20 WM LY294002; p38SAPK, 20 WM
SB203580). None of the inhibitors had any e¡ect at 3 mM
glucose whereas the MEK inhibitor PD98059 decreased the
number of nuclear NeuroD1-expressing cells in 20 mM glu-
cose from 90 to 65% (Fig. 2, P6 0.03), suggesting that acti-
vation of the MEK^ERK pathway stimulates nuclear local-
ization of NeuroD1. In contrast, neither LY294002 nor
SB203580 had a signi¢cation e¡ect.
3.2. Serine 274 of NeuroD1 is involved in the nuclear
translocation response to glucose
To begin to identify the amino acid(s) in NeuroD1 that
mediates nuclear translocation in response to glucose, the po-
tential ERK phosphorylation sites at serine 259, threonine
262, serine 266, and serine 274 were inactivated by mutating
each to alanine. Their e¡ect on sub-cellular distribution of
NeuroD1 was determined immunohistochemically with anti-
HA antibody in transfected cells grown in 25 mM glucose.
The NeuroD1 mutants at serine 259, threonine 262, and serine
266 had a similar cytoplasmic staining fraction when com-
pared to the wild type (Fig. 3). In contrast, the serine to
alanine mutation at position 274 resulted in a marked increase
in the number of cells harboring NeuroD1 in the cytoplasm.
Importantly, a serine 274 to aspartic acid (S274D) mutation
restored wild type-like activity (Fig. 3); this type of mutation
is believed to mimic the phosphorylated state. Together these
results demonstrate that NeuroD1 is translocated to the nu-
cleus in response to stimulating glucose concentrations, a pro-
cess that is partially dependent upon phosphorylation at ser-
ine 274 by the MEK^ERK signalling pathway.
3.3. NeuroD1 trans-AD activity is glucose-responsive and
dependent upon the MEK^ERK signalling pathway
To determine if the transactivation potential of NeuroD1
was regulated by glucose, the C-terminal AD-containing re-
gion (i.e. amino acids 156^355) was analyzed as a fusion with
the DNA-binding domain of the S. cerevisiae Gal4 transcrip-
tion factor. Gal4-NeuroD 156^355 was co-transfected into
MIN6 cells together with a CAT reporter plasmid containing
¢ve GAL4 DNA-binding sites upstream of the E1b TATA
box (G5b-CAT). Gal4-NeuroD 155^356 was roughly three-
fold more active in 20 mM glucose than 3 mM (Fig. 4,
P6 0.02). This level of stimulation is similar to insulin en-
hancer-driven reporter constructs in MIN6 cells [24]. In con-
trast, the relative amount of Gal4-NeuroD nuclear protein
was una¡ected by these conditions (data not shown).
Speci¢c MEK^ERK, PI3K, or p38SAPK signalling inhib-
itors were next tested to determine their involvement in Gal4-
NeuroD 156^355 activation. Only the MEK-speci¢c PD98059
inhibitor reduced glucose-inducible expression; inhibition was
to approximately 50% of wild type (Fig. 4, P6 0.05). In con-
trast, NeuroD1 AD activity tended to increase in both 3 and
20 mM glucose, without signi¢cantly a¡ecting the fold glucose
activation in the presence of the PI3K inhibitor, LY294002.
Collectively, these results suggested that stimulating glucose
conditions in£uence both the level and activity of NeuroD1 in
the nucleus. Furthermore, that the MEK^ERK pathway ap-
pears to mediate these processes.
4. Discussion
NeuroD1 appears to play a vital role in both L-cell-type-
speci¢c and glucose-regulated insulin gene transcription [47].
Mutations within this factor also contribute to L-cell dysfunc-
tion in type 2 diabetes [39]. Our objective here was to begin to
de¢ne how NeuroD1 activity is controlled in glucose-stimu-
lated L-cells. We show that the AD and nuclear partitioning
potential of NeuroD1 are induced by glucose. In addition, the
ability of PD98059 to reduce both of these activities suggests
that MEK^ERK signalling is intimately involved. In contrast,
NeuroD1 activity was una¡ected by speci¢c inhibitors of the
PI3K and p38 SAP kinase pathways, emphasizing the partic-
ular signi¢cance of MEK^ERK signalling in regulation.
Two distinct tagged NeuroD1 fusion proteins, HA-Neu-
roD1 and GFP-NeuroD1, were constructed and used to in-
vestigate whether glucose a¡ected sub-cellular localization.
Importantly, their glucose response pattern was almost iden-
Fig. 2. The MEK-speci¢c PD98059 inhibitor reduces the level of nu-
clear NeuroD1. Fraction of MIN6 cells containing nuclear GFP-
NeuroD1 or HA-NeuroD1. The total number cytoplasmic and
nuclear GFP-NeuroD1- or HA-NeuroD1-transfected cells were
counted and percent of nuclear positive cells calculated as a fraction
of the total. HA-NeuroD1-transfected cells were incubated in the
presence and absence of 50 WM PD98059, 20 WM LY294002, and
20 WM SB203580. Results shown are the mean of three independent
experiments. Error bars represent standard deviation. *Student’s
t-test on 3 vs. 20 mM glucose, **Student’s t-test on 20 mM vs. 20
mM+PD.
Fig. 3. Serine 274 in NeuroD1 mediates nuclear translocation.
MIN6 cells were transiently transfected with the wild type and
S259A, T262A, S266A, S274A, and S274D mutant HA-NeuroD1
and grown in the presence of 25 mM glucose. The HA-NeuroD1-
transfected cells were stained and counted for NeuroD1 expression
as described in Fig. 2. Results shown are the mean of ¢ve indepen-
dent experiments. Error bars represent standard deviation. *Stu-
dent’s t-test on HA-NeuroDS274A compared to wild type (WT).
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tical. Thus, the number of MIN6 cells contain nuclear Neu-
roD1 increased by roughly two-fold in response to 3 versus 20
mM glucose (Fig. 2). In addition, this activity was signi¢-
cantly and speci¢cally attenuated by treatment with the
MEK inhibitor PD98059. The involvement of ERKs in L-
cell function is also supported by two independent observa-
tions. First, glucose stimulates both ERK1 and ERK2 in
MIN6 cells [48]. We have con¢rmed these ¢ndings and have
also shown that neither PKB nor the stress-stimulated p38
SAP kinase was activated by glucose (data not shown). Sec-
ond, PD98059 reduces insulin enhancer-mediated activation in
response to glucose [49]. Collectively, these results strongly
indicate that phosphorylation of NeuroD1 by ERK1 and/or
ERK2 plays a key role in regulation.
Although we have not directly demonstrated that NeuroD1
is phosphorylated by the ERK1 or ERK2, the e¡ect of mu-
tating consensus phosphoacceptor sites within the protein
would indicate that this is the case. Thus, nuclear partitioning
was only a¡ected by a dysfunctional mutation at the potential
phosphoacceptor site at serine 274, and not by others within
the C-terminal AD (i.e. serine 259, threonine 262, and serine
266) (Fig. 3). Signi¢cantly, replacing serine 274 with an as-
partic acid residue did not a¡ect nuclear transport. The neg-
ative charge of the aspartic acid likely mimicked phosphory-
lation of serine 274, strongly suggesting that this modi¢cation
is directly involved in controlling the sub-cellular distribution
of NeuroD1. The mechanisms regulating NeuroD1 partition-
ing between the cytoplasm and nuclei are unknown. Inspec-
tion of NeuroD1 indicates that the protein contains a nuclear
localization (NLS) and nuclear export (NES) sequence, both
of which are located outside the C-terminal AD region [50].
We are currently investigating how the NLS, NES and serine
274 in£uence the sub-cellular distribution of NeuroD1. Phos-
phorylation also regulates the sub-cellular localization of oth-
er transcription factors, including nuclear factor of activated
T-cells [51^53], AFX, FKHR, and FKHR-L1 [54^60], and the
STAT proteins [61].
The activity of the GAL4 chimera containing the C-termi-
nal ADs of NeuroD1 was also responsive to both glucose and
ERK signalling (Fig. 4). However, in contrast to sub-cellular
localization, Gal4-NeuroD 156^355 activation was insensitive
to the serine 274 mutations as well as those at serine 259,
threonine 262, or serine 266 (data not shown). Presumably,
this GAL4 NLS mediates constitutive transport of this chi-
mera to the nucleus, since the potential NeuroD1 NLS was
not present. As a consequence of the site-directed mutant
analysis, it is unclear if the ERKs directly or indirectly in£u-
ence the AD activity of NeuroD1. We are examining if inter-
actions between the insulin gene coactivator, p300, and the C-
terminal region of NeuroD1 may be involved in potentiation
by glucose [28,29].
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